Healthcare-Associated Infections

Learning Objectives

Introduction

At the end of this module, the learner will be able to:

  • Describe the adverse health and economic consequences of healthcare-associated infections.
  • Summarize how surveillance of healthcare-associated infections is performed and how these data can be used for local quality-improvement activities.
  • Discuss how public reporting of healthcare-associated infection data is being implemented and used by healthcare consumers and payers.

Device Associated Infections

At the end of this module, the learner will be able to:

  • Describe the pathogenesis of CLABSI, CAUTI and VAP.
  • List the most effective strategies to prevent CLABSI, CAUTI and VAP.
  • Explain the difference between surveillance definitions for device-associated infections and the clinical syndromes, and explain why the difference exists.

Multidrug-Resistant Organisms: MRSA, CRE, VRE, ESBL

At the end of this module, the learner will be able to:

  • State the definition of multidrug resistance, common mechanisms of resistance, and identify organisms which are typically classified as Multidrug-Resistant Organisms (MDROs).
  • Compare and contrast the differences in resistance testing conducted using phenotypic and genotypic methods.
  • Identify the impact of common Multidrug-Resistant Organisms (MDROs) in the care of hospitalized patients.
  • Describe the differences between vertical and horizontal transmission, and discuss the interventions that prevent the emergence and spread of MDROs.

C. difficile

At the end of this module, the learner will be able to:

  • Summarize risk factors for C. difficile infection
  • Discuss testing strategies for detecting C. difficile infection including limitations and factors which may impact testing outcomes
  • Describe transmission-based precautions and environmental cleaning practices to prevent the spread of C. difficile 

Surgical Site Infections

At the end of this module, the learner will be able to:

  • Define the frequency and impact of SSI.
  • Describe the epidemiology and risk factors of SSI.
  • Identify prevention strategies especially as they impact physicians in training.
Course summary
Course opens: 
03/01/2019
Course expires: 
03/01/2021

Introduction

Christopher Crnich, MD
Associate Professor of Medicine
University of Wisconsin School of Medicine & Public Health
No relevant financial disclosures

 

Device Associated Infections

E. Yoko Furuya, MD, MS
Associate Professor of Medicine
Columbia University Medical Center
No relevant financial disclosures

 

Multidrug-Resistant Organisms: MRSA, CRE, VRE, ESBL

Sorabh Dhar, MD
Assistant Professor of Medicine
Wayne State University
No relevant financial disclosures

Teena Chopra, MD, MPH
Infectious Disease Fellow
Wayne State University
Consulting Fee: Shinogi, Tetraphase;
Speakers Bureau: Allergan, Merck

Anupama Neelakanta, MD, MPH
Infectious Disease Fellow
Wayne State University
No relevant financial disclosures
Keith Kaye, MD
Professor of Medicine
Wayne State University
No relevant financial disclosures
Sarit Sharma, MD
Professor of Community Medicine,
Dayanand Medical College & Hospital
No relevant financial disclosures
  

 

C. difficile

Lead Author:

David Banach, MD, MPH
Associate Professor of Medicine
UConn Health
No relevant financial disclosures

Assisting Author:

Sarah Haessler, MD, MS
Hospital Epidemiologist
Baystate Medical Center
No relevant financial disclosures

Surgical Site Infections

Lead Author:

Julie Trivedi, MD
Medical Director of Infection Prevention
UTSouthwestern Medical Center
No relevant financial disclosures

Assisting Author:

Jennifer Hanrahan, DO, MSc
Associate Professor
MetroHealth Medical Center
No relevant financial disclosures

Assisting Author:

Trish Perl, MD, MSc
Professor of Medicine
Johns Hopkins University
No relevant financial disclosures

Available Credit

Accreditation Period

Course opens: 
03/01/2019
Course expires: 
03/01/2021
Please login or register to take this course.